Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

STC-15

Small molecule · Inhibitor of METTL3 (methyltransferase-like protein 3) (METTL3) · developed by STORM Therapeutics

Phase 1/2 Most advanced trial

1 Registered trials

What is STC-15?

STC-15 is an orally bioavailable inhibitor of METTL3, the RNA methyltransferase that deposits N-6-methyladenosine (m6A) on mRNA and lncRNA. By blocking METTL3, it reduces m6A marks, which triggers double-stranded RNA formation, interferon signaling and activation of anti-tumor T cells. It is being studied in solid tumors, including sarcoma, leiomyosarcoma and dedifferentiated liposarcoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Small molecule
Targets: METTL3 (methyltransferase-like protein 3) (METTL3)
Mechanism: Inhibitor of METTL3 (methyltransferase-like protein 3) (METTL3)
Pathways: m6A mRNA methylation, innate immunity / interferon signaling, cytotoxic T-lymphocyte activation, anti-apoptotic gene expression
Therapy area: Oncology
Developer: STORM Therapeutics LTD
In trials of: CHRS
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII: F729CY2V48

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06975293	Phase 1/2	Solid Tumor	Recruiting	CHRS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Dedifferentiated LiposarcomaLeiomyosarcomaSarcomaSolid Tumor

Sources

Updated Oct 11, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z